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S-100B and FDG-PET/CT in therapy response assessment of
melanoma patients
Abstract
OBJECTIVE: To compare the value of the tumor marker S-100B protein and fluorodeoxyglucose
positron emission tomography/computed tomography (FDG-PET/CT) in patients treated for melanoma
metastases. 
METHODS: In 41 patients with proven melanoma metastases, S-100B measurements and FDG-PET/CT
were performed before and after therapy. The change of S-100B levels (DeltaS-100B) was assessed. In
all patients, therapy response was assessed with PET/CT using visual criteria and change of maximal
standard uptake value (DeltaSUV(max.)) or total lesion glycolysis (DeltaTLG). 
RESULTS: In 15 of 41 patients (37%), S-100B values were not suitable because they were normal
before and after therapy. In 26 patients, S-100B was suitable for therapy response assessment. PET/CT
was suitable for response assessment in all patients. Correlations between DeltaS-100B and DeltaTLG (r
= 0.850, p < 0.001) and between DeltaS-100B and DeltaSUV(max.) (r = 0.818, p < 0.001) were both
excellent. A complete agreement between S-100B and PET/CT response assessment was achieved in 22
of 26 patients. In 4 patients, therapy response differed between the S-100B and PET/CT findings, but
subsequent S-100B measurements realigned the S-100B results with the later PET/CT findings. 
CONCLUSION: In a third of our patients with metastases, the S-100B tumor marker was not suitable
for therapy assessment. In these patients, imaging techniques remain necessary, and FDG-PET/CT can
be used for response assessment.
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tween the S-100B and PET/CT findings, but subsequent
S-100B measurements realigned the S-100B results with the 
later PET/CT findings.  Conclusion: In a third of our patients 
with metastases, the S-100B tumor marker was not suitable 
for therapy assessment. In these patients, imaging tech-
niques remain necessary, and FDG-PET/CT can be used for 
response assessment.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Serum S-100B protein is a useful tumor marker in mel-
anoma patients, reflecting the tumor burden. In addition, 
S-100B has prognostic implications  [1–9] .
 Since the 90s, fluorodeoxyglucose positron emission 
tomography (FDG-PET) has been increasingly used to 
image patients with melanoma. Recent publications dem-
onstrated that FDG-PET/CT has a high accuracy for N 
and M staging in melanoma patients and that it is supe-
rior to PET alone, CT alone or conventional imaging 
methods  [10, 11] . PET and PET/CT are increasingly used 
for therapy response assessment in different malignant 
tumors like lymphoma  [12] , esophageal cancer  [13, 14] , 
lung cancer  [15] , breast cancer  [16] and others  [17, 18] in 
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 Abstract 
 Objective: To compare the value of the tumor marker S-100B 
protein and fluorodeoxyglucose positron emission tomog-
raphy/computed tomography (FDG-PET/CT) in patients 
treated for melanoma metastases.  Methods: In 41 patients 
with proven melanoma metastases, S-100B measurements 
and FDG-PET/CT were performed before and after therapy. 
The change of S-100B levels (  S-100B) was assessed. In all 
patients, therapy response was assessed with PET/CT using 
visual criteria and change of maximal standard uptake value 
(  SUV max. ) or total lesion glycolysis (  TLG).  Results: In 15 of 
41 patients (37%), S-100B values were not suitable because 
they were normal before and after therapy. In 26 patients,
S-100B was suitable for therapy response assessment. PET/
CT was suitable for response assessment in all patients.
Correlations between   S-100B and   TLG (r = 0.850, p  ! 
0.001) and between   S-100B and   SUV max.  (r = 0.818, p  ! 
0.001) were both excellent. A complete agreement between 
S-100B and PET/CT response assessment was achieved in 22 
of 26 patients. In 4 patients, therapy response differed be-
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the neoadjuvant and adjuvant situation, but publications 
regarding PET or PET/CT for therapy response assess-
ment in melanoma patients are very limited.
 With the ongoing development of postprocessing soft-
ware for PET/CT examinations, it is now possible to rou-
tinely assess several semiquantitative parameters such as 
standard uptake value (SUV) and total lesion glycolysis 
(TLG) which may – similar to the S-100B tumor mark-
er – reflect the tumor burden  [19] .
 The aim of this study was to compare the value of the 
tumor marker S-100B and FDG-PET/CT in patients 
treated for melanoma metastases by comparing the val-
ues of S-100B with PET/CT findings including measure-
ments of TLG and maximum SUV (SUV max. ) before and 
after therapy.
 Materials and Methods 
 Patients 
 Our institution is a teaching and tertiary-care hospital and a 
major referral site for patients with malignant melanoma.  Retro-
spectively, out of 210 in-house patients with high-risk melanoma 
imaged with PET/CT at our institution, 41 (22 female, 19 male; 
mean age 57.5 years, range 25–82 years) were identified who ful-
filled the following criteria: (1) diagnosis of melanoma with his-
tologically or cytologically proven lymph node, in-transit or dis-
tant metastases; (2) availability of S-100B measurements before 
and after therapy; (3) FDG-PET/CT performed before and after 
therapy synchronously with the S-100B measurements, and (4) 
treatment of the metastases between the two PET/CT scans and 
S-100B measurements. We received approval from our institu-
tional review board to undertake this study.
 Determination of S-100B 
 The determination of S-100B was done with a commercially 
available immunoassay kit (Sangtec 100 ELISA, Dia Sorin Inc., 
Stillwater, N.Mex., USA) according to the instructions of the 
manufacturer. The normal range of 0.0–0.2   g/l was determined 
from samples of 100 healthy blood donors.
 PET/CT Imaging 
 All the data were acquired on a combined PET/CT in-line sys-
tem (Discovery LS or Discovery ST, GE Health Systems, Milwau-
kee, Wisc., USA). These dedicated systems integrate a PET scan-
ner (GE Advance Nxi, GE Health Systems) with a multislice heli-
cal CT (Lightspeed plus or Lightspeed 16; GE Health Systems) and 
permit the acquisition of coregistered CT and PET images in one 
session.
 Patients fasted for at least 4 h prior to the scanning, which 
started approximately 60 min (mean 61.4 min, SD  8 5.38) after 
the injection of 370–400 MBq (mean 382.4, SD  8 10.5) of  18 F-
FDG. All patients were tested for a normal glucose level (range 
80–120 mg/dl, 4.4–6.7 mmol/l) before scanning. Patients with 
elevated glucose levels were rescheduled and scanned with nor-
mal glucose levels. An oral CT contrast agent (Micropaque Scan-
ner, Guerbet AG, Aulnay-sous-Bois, France) was given 15 min 
before the injection of  18 F-FDG. Patients were examined in the 
supine position. No intravenous contrast agent was given. Ini-
tially, the CT scan was acquired starting from the level of the 
head using the following parameters: 40 mAs, 140 kV, 0.5 s/tube 
rotation, slice thickness 4.25 mm, scan length 867 mm, data ac-
quisition time 22.5 s. The CT scan was acquired during breath 
holding in the normal expiratory position. In the patients with 
primary tumors of the lower extremities, scanning of the lower 
legs was added.
 Immediately following the CT image acquisition, a PET emis-
sion scan was made with an acquisition time of 3 min/cradle posi-
tion with a 1-slice overlap in 2-dimensional mode (matrix 128  ! 
128). The 8–9 cradle positions starting from the head to the knees 
resulted in an acquisition time of approximately 24–27 min. In 
the patients with primary tumors of the lower extremities, scan-
ning of the lower legs was added. The CT data were used for the 
attenuation correction, and the images were reconstructed using 
a standard iterative algorithm (OSEM). The acquired images were 
viewed with a software providing multiplanar reformatted im-
ages of PET alone, CT alone and fused PET/CT with linked cur-
sors using a Xeleris workstation (GE Health Systems). PET/CT 
imaging was performed according to the recently published ‘Pro-
cedure guideline for tumor imaging with  18 F-FDG PET/CT 1.0’ 
 [20] .
 Measurement of SUV max.  and TLG 
 The images were reviewed and analyzed by two experienced 
nuclear-radiology physicians without knowledge of the results of 
other imaging studies. The PET images and the corresponding 
CT images of the PET/CT study were analyzed for the presence 
and nature of focal lesions with an increased  18 F-FDG uptake. For 
all patients, the attenuation-corrected PET images were analyzed. 
Lesions were interpreted as metastases if the uptake was higher 
than that of the surrounding background tissue and thus a focal 
lesion was clearly depictable.  18 F-FDG uptake in physiological or 
benign variants as in muscles or pulmonary infiltration was ex-
cluded from the analysis.
 Semiquantitative analysis of FDG uptake in all suspicious le-
sions was performed by measuring the SUV max. . In our institu-
tion, SUV is corrected for lean body mass (LBM). A personal scale 
(Tanita, model 2001; Tanita, Tokyo, Japan) with an integrated 
foot-to-foot bioelectric impedance analyzer was used to deter-
mine the LBM of the patients. The manufacturer supplied equa-
tions for this model incorporating sex, mass, height and a mea-
sured impedance value to determine the percentage of body fat 
and for the calculation of LBM. By using attenuation-corrected 
PET data, SUV max.  was calculated with the following equation by 
creating a freehand region of interest over the complete visible le-
sion on the fused PET/CT image: SUV max.(LBM)  = (LBM – C FDG )/
dose where LBM is measured in grams, C FDG  is the concentration 
of  18 F-FDG in becquerels per milliliter, and dose is the injected 
dose measured in becquerels.
 Simultaneously, TLG was determined in every PET/CT exam-
ination. TLG is a composite parameter that represents the total 
lesion glycolysis and thus incorporates both the whole body extent 
and degree of abnormal FDG uptake which was calculated for 
each PET/CT data set. A 3-dimensional region of interest was 
drawn around the lesions, and the TLG was determined auto-
matically by accumulating the SUV of all pixels in the volume. 
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This parameter is subject to some interobserver reproducibility 
issues; so, as a compromise between accuracy, reproducibility and 
simplicity, a threshold value was chosen at 1.5 and all SUV values 
above this, in lesions identified as abnormal, were summed and 
incorporated as a single value. This SUV threshold was prospec-
tively chosen from experience in prior studies where this value 
was found to effectively exclude most areas of normal FDG uptake 
apart from the heart, the bladder and, sometimes, the liver. The 
PET/CT pairs were also analyzed side by side to further reduce 
issues of variability in drawing regions of interest in FDG-avid 
disease where the background SUV max.  was  1 1.5.
 Therapy Response Assessment with S-100B 
 In all patients S-100B levels were determined before (S-100B 1) 
and after treatment (S-100B 2). The change of S-100B levels
(  S-100B = S-100B 1 – S-100B 2/S-100B 1) was assessed. An in-
crease in S-100B after therapy of  1 25% was determined as pro-
gressive disease (PD), an increase of less than 25% or a decrease 
of less than 25% was determined as stable disease (SD), a decrease 
of more than 25% was determined as partial response (PR) and a 
decrease from a pathologically elevated S-100B value to a normal 
value ( ^  0.2   g/l) was determined as complete response (CR).
 Therapy Response Assessment with PET/CT 
 According to the calculations of   S-100B,   TLG (  TLG = 
TLG 1 – TLG 2/TLG 1) and   SUV max.  (  SUV max.  = SUV max.  1 – 
SUV max.  2/SUV max.  1) were calculated. Therapy response assess-
ment with PET/CT was determined with a combination of PET 
and CT criteria: PD was diagnosed in patients with increasing size 
and/or FDG uptake ( 1 25%) in the known metastases or if new 
metastases were detected. SD was diagnosed if there was no sig-
nificant change ( ! 25%) in size and FDG uptake in the known 
metastases. PR was diagnosed if the size and FDG uptake of the 
lesions were more than 25% but FDG uptake higher than 1.5 re-
mained in the metastases. CR was determined as complete disap-
pearance of pathological FDG uptake in the metastases. The size 
of the lesions was measured on the CT part of the PET/CT. If new 
FDG-negative pulmonary nodules developed between the base-
line and the restaging investigation which were not calcified, this 
was described as PD due to lung metastases.
 Fig. 1. 72-year-old male patient (No. 29) after resection of an ul-
cerating melanoma (Breslow 5.3 mm) at the right knee 3 years 
before.  a Baseline PET/CT showing multiple metastases (right col-
umn, maximum intensity projection image, arrows) involving the 
lung, liver, retroperitoneal lymph nodes (right column, axial im-
ages, arrows) and soft tissue. S-100B was 0.6   g/l, TLG 106,791 
and SUV max.  29.5 initially.  b After chemotherapy S-100B de-
creased to a normal value (0.1   g/l), and PET/CT demonstrated a 
complete disappearance of pathological FDG uptake and normal-
sized lymph nodes (arrows) indicating a complete remission. 
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 Statistical Analysis 
 Data were analyzed on a patient basis using SPSS 13 (SPSS 
Inc.). Correlations between changes in tumor markers and PET/
CT findings were derived using Spearman’s rank correlation.
 Results 
 S-100B Compared with SUV max.  and TLG 
 In 15 of 41 patients (37%), S-100B values were not suit-
able because they were normal before (median 0.1   g/l; 
mean 0.11   g/l; range 0.0–0.2   g/l) and after (0.06   g/l; 
0.1   g/l; 0.0–0.1   g/l) therapy. Four of these patients had 
lymph node and 11 distant metastases. In 26 patients,
S-100B was suitable for therapy response assessment with 
median values of 0.6   g/l (mean 1.7   g/l; range 0.1–14.3 
  g/l) before and 0.3   g/l (0.96   g/l; 0.0–7.3   g/l) after 
therapy. In 4 of these 24 patients, the initial S-100B was 
normal (0.2   g/l; 0.18   g/l; 0.1–0.2   g/l) and increased 
to abnormal values after therapy (0.75   g/l; 0.78   g/l; 
0.5–1.1   g/l). Four of these patients had regional lymph 
node metastases, 21 distant metastases and 1 in-transit 
metastases ( fig. 1–3 ).
 The mean SUV max.  was abnormal ( 1 1.5) before thera-
py in all patients (median 8.9; mean 10.6; range 1.7–58.0). 
After therapy the median SUV max.  was 2.7 (8.9; 1.0–65.7). 
In 17 patients, the SUV max.  was  ! 1.5 after therapy.
 The mean TLG was measurable in all patients with a 
median value of 105,829 (mean 544,029; range 3,503–
7,389,386) before therapy and was not measurable any-
more in 17 patients after therapy. In the remaining 24 
patients, the median TLG after therapy was 68,654 (mean 
1,811,591; range 1,242–20,215,306). Both correlations be-
tween   S-100B and   TLG (r = 0.850, p  ! 0.001) as well as 
between   S-100B and   SUV max.  (r = 0.818, p  ! 0.001) 
were excellent. The results are summarized in  table 1 as 
well as  figures 4 and  5 .
 Fig. 2. 48-year-old female patient (No. 3) 2 years after resection of 
a malignant melanoma at the right elbow (unknown Breslow 
stage).  a Initial PET/CT showing metastases in the subcutaneous 
soft tissue (upper arrow), in the right L 2  nerve root (middle arrow 
and arrow on the right-sided axial fused PET/CT image) and phys-
iological FDG uptake in the right ovary (lower arrow). S-100B was 
initially normal (0.0   g/l), TLG was 14,915 and SUV max.  5.3. Ad-
ditional physiological FDG uptake in the supraclavicular brown 
fatty tissue is seen. Both metastases were resected, and S-100B was 
normal (0.0   g/l) 3 months after the operation.  b Simultaneously 
performed PET/CT was normal showing only the operation de-
fects (arrow on the right-sided fused axial PET/CT image). 
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 Fig. 3. 66-year-old male patient (No. 40) 4 years after resection of 
a lumbar malignant melanoma (Breslow 1.4 mm).  a Baseline PET/
CT showing multiple lung (arrows) and a large liver metastasis 
(right-sided fused axial PET/CT image, arrow). S-100B was elevat-
ed at 12.6   g/l. TLG1 was 690,016, and SUV max.  was 14.6.  b After 
treatment with chemotherapy, S-100B dropped to 3.1 indicating a 
PR but PET/CT showed PD with new metastases in retroperi-
toneal lymph nodes (arrows). In this case TLG (797,938) and
SUV max.  (17.6) both increased. Brain metastases were detected in 
brain CT. The patient died 5 months later. 
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 Fig. 4. Correlation between   S-100B and   TLG in 26 patients.  Fig. 5. Correlation between   S-100B and   SUV max.  in 26 pa-
tients. 
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 S-100B Compared with FDG-PET/CT regarding 
Therapy Response 
 In 15 (37%) patients, S-100B was not suitable for the 
comparison because the values were normal before and 
after therapy although the patients had proven metasta-
ses (11 patients with distant metastases and 4 with lymph 
node metastases). Ten of these patients had CR in PET/CT 
follow-up after therapy, 4 had PD and 1 patient SD. In 26 
patients, behavior of S-100B and PET/CT findings could 
be compared. Altogether there was an excellent correla-
tion between response assessment with S-100B and PET/
CT (r = 0.923, p  ! 0.001). The results of therapy assess-
Table 1. Results of S-100B, TLG and SUVmax. measurements, localization of metastases and treatment in 41 patients
Patient
No.
S-100B 1
g/l
S-100B 2
g/l
TLG 1 TLG 2 SUVmax. 1 SUVmax. 2 Initial localization of metastases Therapy
1 0.0 0.0 3,503 n.m. 3.8 1.4 lung, spleen, soft tissue, inguinal LN chemo
2 0.0 0.0 141,249 n.m. 10.5 1.2 adrenal surgery
3 0.0 0.0 14,915 n.m. 5.3 1.1 lumbar nerve root, subcutis surgery
4 0.0 0.0 538 n.m. 1.7 1.1 inguinal LN surgery
5 0.1 0.1 32,452 85,628 7.7 10.3 lung chemo
6 0.1 0.1 54,636 41,141 4.5 7.1 lung, bile duct surgery
7 0.1 0.5 341,324 1,440,501 21.1 24.9 intestine, mesenteric LN, muscle chemo
8 0.1 0.1 29,700 n.m. 8.0 1.1 inguinal LN surgery
9 0.1 0.1 1,001,432 n.m. 18.0 1.2 vagina surgery/RT
10 0.1 0.1 652,892 1,937,027 8.1 65.7 bone, LN chemo
11 0.1 0.1 38,137 n.m. 3.5 1.3 lung, liver, LN chemo
12 0.1 0.1 196,354 26,011 10.8 7.5 liver surgery
13 0.2 0.6 393,584 1,302,455 6.2 11.8 LN, soft tissue chemo
14 0.2 0.1 14,544 33,072 7.1 9.7 brain, cervical LN chemo
15 0.2 0.0 84,242 1,242 7.5 1.8 cervical LN surgery
16 0.2 0.0 77,371 n.m. 10.3 1.3 lung chemo
17 0.2 1.1 163,804 1,333,843 4.8 7.3 liver, bone chemo
18 0.2 0.9 25,567 51,680 3.6 6.1 lung, iliac LN chemo
19 0.2 0.1 32,778 n.m. 9.3 1.2 iliac LN surgery
20 0.3 0.1 49,913 n.m. 10.0 1.3 iliac LN surgery
21 0.3 0.2 262,281 101,394 6.0 5.5 iliac and mediastinal LN chemo
22 0.3 0.6 126,543 127,315 5.5 5.5 liver, cervical LN, subcutis chemo
23 0.3 0.1 124,416 n.m. 3.6 1.0 liver, bone, LN chemo
24 0.3 0.0 27,894 n.m. 6.1 1.1 leg surgery
25 0.5 0.7 83,546 40,122 6.8 9.1 lung, liver chemo
26 0.5 0.1 21,717 n.m. 8.9 1.4 inguinal LN surgery
27 0.5 0.0 106,368 n.m. 10.0 1.1 bone surgery
28 0.6 0.2 105,829 5,278 6.4 2.7 lung, mediastinal LN chemo
29 0.6 0.1 106,791 n.m. 29.5 1.3 lung, liver, LN, subcutis chemo
30 0.6 3.3 717,473 9,084,700 13.7 52.6 lung chemo
31 0.6 0.1 97,803 5,736 10.5 2.6 supraclavicular, axillary LN surgery
32 0.6 0.5 4,468,813 4,745,458 58.0 49.8 lung, soft tissue chemo
33 0.8 0.3 20,419 40,861 9.3 4.4 lung, cervical LN surgery
34 0.9 4.2 23,930 28,604 3.5 3.4 bone RT
35 1.2 0.3 347,905 213,111 17.1 8.7 lung, cutis/subcutis, muscle chemo
36 1.3 0.1 166,938 n.m. 15.1 1.1 lung chemo
37 1.6 0.0 48,045 n.m. 11.0 1.3 inguinal LN surgery
38 1.7 0.2 709,785 8,185 9.8 2.6 liver, bone, lung, muscles, LN chemo
39 2.5 7.3 7,389,386 20,215,306 14.7 24.5 liver, retroperitoneal LN, subcutis chemo
40 12.6 3.1 690,016 797,938 14.6 17.6 liver, lung chemo
41 14.3 0.3 3,310,349 1,686 13.3 3.2 liver, adrenal, subcutis, LN chemo
LN = Regional lymph node; chemo = chemotherapy; RT = radiotherapy.
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ment are summarized in  table 2 . In 22 of these 26 patients 
(85%), there was complete agreement regarding therapy 
response. Nine patients had PD, 3 patients PR and 10 pa-
tients CR with both methods. In 4 patients there was a 
discrepancy in the assessment of therapy response. In 2 
patients S-100B showed a PR and PET/CT a PD, in 1 pa-
tient S-100B showed a CR and PET/CT an SD and in 1 
patient S-100B showed SD and PET/CT PD.
 The details and follow-up of the patients with incon-
sistent findings are summarized in  table 3 revealing that 
by the next measurement of S-100B 3–4 months later 3/4 
patient responses were again in complete agreement with 
the PET/CT findings. In the other patient, no further S-
100B value was obtained. Hence within 3 months of the 
posttherapy study, there was complete agreement be-
tween S-100B and PET/CT in 25/26 cases.
 Discussion 
 Because of the considerable number of patients with 
proven metastases but normal S-100B values, imaging 
techniques such as PET/CT are necessary to assess tumor 
load and response to therapy in metastatic melanoma. 
However, in the subgroup of patients with an abnormal 
S-100B prior to therapy, there was an excellent correlation 
between the change in S-100B and the change in qualita-
tive and semiquantitative PET/CT findings in patients 
treated for melanoma metastases.
 Although the effect of chemotherapy in stage IV mel-
anoma patients is still disappointing, many patients with 
metastases are included in clinical trials where therapy 
response has to be assessed  [21] . Research on melanoma 
is ongoing, and promising therapy results have been pub-
lished recently  [22, 23] . As soon as an effective therapy of 
stage IV melanoma becomes available, the need for ac-
curate therapy response assessment will increase dramat-
PET/CT
PD SD PR CR not suitable
S-100 PD 9 0 0 0 0
SD 1 0 0 0 0
PR 2 0 3 0 0
CR 0 1 0 10 0
Not suitable 4 1 0 10 0
Table 3. Follow-up of patients with discrepant therapy response results
Patient
No.
S-100B PET/CT Follow-up Survival
40 PR PD Patient progressed under chemotherapy. Brain CT showed multiple brain metastases.
Contrast-enhanced CT 4 months after PET/CT 2 showed progression of distant 
 metastases in the liver, lung and lymph nodes and ascites. Patient died 5 months after 
the last PET/CT. No more S-100B measurements performed.
5 months
33 PR PD PET/CT 3 and 6 months later confirmed progression with new metastases in the liver, 
lymph nodes and soft tissue. S-100B 3 months later showed increase to 0.6 g/l.
After 6 months alive 
with progression
21 CR SD PET/CT 2 months later showed again SD and after 4 months PD with multiple new 
bone and lymph node metastases and new brain metastases. S-100B after 4 months 
 increased to 0.5 g/l. Resection of brain metastases performed after 5 months.
After 5 months alive 
with progression
32 SD PD PET/CT after 3 months showing progression with new abdominal metastases.
S-100B after 3 months increased to 0.7 g/l.
After 3 months alive 
with progression
Table 2. Therapy response assessment 
with S-100B and FDG-PET/CT
 S-100B and FDG-PET/CT in Assessment 
of Melanoma 
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ically. The data of Henze et al. [5] support the value of 
serum S-100B as a clinical marker for monitoring therapy 
response of metastatic melanoma during systemic thera-
pies. FDG-PET/CT is increasingly used for therapy as-
sessment of different tumors  [24, 25] . Current data re-
garding the therapy assessment of melanoma patients 
with PET or PET/CT are limited to some case reports 
showing the effect of limb perfusion therapy  [26] . To our 
knowledge, this is the first study comparing the behavior 
of S-100B and FDG-PET/CT in the therapy assessment of 
melanoma patients. The major drawback for the S-100B 
in our study population was that 15 of the patients with 
proven metastases (11 with distant metastases, 4 with 
lymph node metastases) had normal S-100B values before 
therapy. Patients with lymph node metastases more often 
show normal or lower S-100B values compared with pa-
tients with distant metastases because of the lower tumor 
burden  [27] .
 In many clinical trials, CT remains the imaging mo-
dality of choice for therapy assessment in patients with 
stage IV melanoma. The big advantage of PET/CT is that 
this method provides the combination of morphological 
and metabolic information. A recently published study 
compared FDG-PET/CT imaging for N and M staging of 
250 consecutive melanoma patients with PET alone and 
CT alone; it showed that the accuracy of PET/CT for M 
staging was significantly higher than that of PET alone 
and CT alone (98 vs. 93 and 84%)  [27] .
 The simplest method for therapy assessment is a vi-
sual analysis by comparing the baseline and posttherapy 
scans. Another possibility is the use of semiquantitative 
measurements like SUV max.  or average SUV. This ap-
proach takes a little more time if multiple lesions are pres-
ent but is highly reproducible. From a theoretical point of 
view, TLG might be the parameter which represents the 
‘real’ tumor burden because size and FDG uptake of all 
lesions are assessed. The experience with TLG for therapy 
response assessment is limited and only a few publica-
tions have incorporated this parameter  [19, 28] . The dis-
advantage of the TLG approach is that an arbitrary 
threshold has to be found which we set in our study to an 
SUV of 1.5. We found that especially in organs with high 
background uptake like the liver TLG measurement 
might be difficult. Nevertheless, the correlation between 
  S-100B and   SUV max.  as well as   TLG was excellent as 
was the correlation of therapy response assessment be-
tween S-100B and PET/CT findings based on visual or 
SUV max.  measurements. This study suggests that the 
time-consuming measurement of TLG in daily routine is 
not needed, and, if semiquantitative measurement is felt 
to be necessary, SUV max.  is an easily measured and high-
ly reproducible alternative.
 The poor sensitivity of PET in detecting brain metas-
tases is well known due to the high physiological uptake 
in the normal brain. So in this region MRI is the imaging 
gold standard in the detection of metastases  [29] . In our 
patients we had 1 case where PET/CT clearly showed pro-
gression of distant metastases in the liver and lung but 
missed new brain metastases developed during systemic 
therapy which were detected with brain MRI. S-100B 
falsely indicated a PR with a decrease from 12.6 to 3.1 
  g/l. This case underlines the fact that additional brain 
MRI is strongly recommended for complete therapy re-
sponse assessment especially in patients with cerebral 
symptoms.
 Our study has several limitations. This is a retrospec-
tive study and has a selection bias because only patients 
with available S-100B values and simultaneously per-
formed PET/CT examinations before and after therapy 
were included. Further limitations are the relatively lim-
ited number of patients, a reason why the statistical cal-
culations should be interpreted carefully. So far, we can-
not present outcome data because the follow-up time at 
this time point is not long enough. Also, the group of pa-
tients in this study is too inhomogeneous with stage III 
and stage IV melanomas and different treatments includ-
ing surgery, radiotherapy and different systemic thera-
pies. In an ongoing study we are investigating S-100B and 
PET/CT in the therapy response assessment of stage IV 
melanoma patients by comparing both methods with the 
outcome of the patients.
 Interestingly, in all 4 patients with inconsistent find-
ings, PET/CT showed a poorer therapy response com-
pared with the S-100B assessment. The clinical and imag-
ing follow-up of all these confirmed the results of the 
PET/CT and showed progression in 3 patients and SD fol-
lowed by progression in 1 patient. It seems that S-100B 
has the tendency to underestimate the tumor burden or 
in other words to overestimate the therapy response in 
some patients.
 Our results suggest that therapy response assessment 
with S-100B might be sufficient if the value is abnormal 
before implementation of the therapy, particularly if there 
is planned frequent measurement of this parameter and 
where it remains stable or falls. However, when the S-
100B shows a progressive increase, a PET/CT scan may be 
indicated because the location and extent of disease may 
govern the most appropriate therapy in such cases. Fur-
ther, the use of other imaging modalities such as MRI 
may also be necessary for the early detection of brain me-
 Strobel et al.
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tastases or metastases compromising the spinal canal. So 
decisions when to use imaging or just S-100B in the as-
sessment of therapy need to be made on a patient-by-pa-
tient basis after careful consideration of their clinical sta-
tus and have to be evaluated in further studies with larg-
er patient numbers.
 In conclusion, there is an excellent correlation between 
the S-100B tumor marker and PET/CT findings regard-
ing therapy response assessment in patients treated for 
melanoma metastases where the S-100B marker is abnor-
mal. However, in one third of patients with melanoma 
metastases, the S-100B tumor marker is not suitable for 
therapy response assessment. In these patients PET/CT 
should be used as the primary imaging modality. PET/CT 
has a high accuracy to precisely localize the involved an-
atomic sites and to find the adequate treatment. The cri-
teria for accurate response assessment with PET/CT have 
to be defined in prospective studies, but it is clear from 
our study that the more complex and complicated TLG 
measurement is no better than the simpler and more re-
producible SUV max.  measurement.
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